Point72 Asia (Singapore) Pte. Ltd. Biocryst Pharmaceuticals Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 72,666 shares of BCRX stock, worth $612,574. This represents 0.09% of its overall portfolio holdings.
Number of Shares
72,666Holding current value
$612,574% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$168 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$158 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$106 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$78.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$74.4 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.57B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...